Stevanato Group Investor Relations

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

Latest News

Stevanato Group Reports First Quarter 2022 Financial Results

View Press Release

Stevanato Group Publishes Materials for 2022 Annual General Meeting

View Press Release

Stevanato Group and Owen Mumford Sign Exclusive Collaboration Agreement for the Innovative Aidaptus® Auto-Injector

View Press Release

Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions With an On-body Device

View Press Release

Latest Financial Results

Q1 2022

Quarter Ended Mar 31, 2022

Earnings Release
PDF HTML
Audio
Earnings Webcast

We respect your privacy. We do not sell, rent, or loan any information to any third party.
Any information you give us is held with the utmost care and security, and will be used
only in ways indicated in our Privacy Policy.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Report Links

IR Contacts

Company

Stevanato Group S.p.A.
Via Molinella 17
Piombino Dese, Padua 35017
Italy

Investor Relations

Lisa Miles
Senior Vice President, Investor Relations
IR@stevanatogroup.com

Transfer Agent

Computershare Trust Company, N.A.
150 Royall Street
Canton, MA 02021